Archive | spotlight-2017

Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human

Continue Reading

Individualized cancer immunotherapy

Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach

Continue Reading

THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

Mainz, September 2017 – TRON will also participate at the THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE in Mainz this year. Meet and talk to our experts in: Bioinformatics: Wednesday, 12:30-2:00 pm Next Generation Sequencing: Wednesday, 3:00-4:00 pm Biomarker: Thursday, 11:30-1:00 pm Immunomonitoring: Thursday, 3:00-4:00 pm Pre-Clinical Research: Friday, 12:30-2:00 pm T-cell Vaccines & Immunotherapy: Friday,

Continue Reading

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their

Continue Reading